Tumour mutational burden: primary versus metastatic tissue creates systematic bias
Tumour mutational burden (TMB) has emerged as a reproducible biomarker to predict immunotherapy response across multiple cancer types. However, a key aspect of TMB measurement that is often overlooked is the source of tissue sample used, which creates a potential for systematic bias. The predominant...
| Hlavní autoři: | , , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
Elsevier
2019-12-01
|
| Edice: | Immuno-Oncology and Technology |
| Témata: | |
| On-line přístup: | http://www.sciencedirect.com/science/article/pii/S2590018819300395 |